Cas:67990-27-6 2,2′-[(3,3′-dimethyl[1,1′-biphenyl]-4,4′-diyl)bis(azo)]bis[4-nonylphenol] manufacturer & supplier

We serve Chemical Name:2,2′-[(3,3′-dimethyl[1,1′-biphenyl]-4,4′-diyl)bis(azo)]bis[4-nonylphenol] CAS:67990-27-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

2,2'-[(3,3'-dimethyl[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[4-nonylphenol]

Chemical Name:2,2′-[(3,3′-dimethyl[1,1′-biphenyl]-4,4′-diyl)bis(azo)]bis[4-nonylphenol]
CAS.NO:67990-27-6
Synonyms:C.I. SOLVENT YELLOW 107);Solvent Yellow 107
Molecular Formula:C44H58N4O2
Molecular Weight:674.95700
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:807.4ºC at 760 mmHg
Density:1.06 g/cm3
Index of Refraction:1.569
PSA:89.90000
Exact Mass:674.45600
LogP:14.79860

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like C.I. SOLVENT YELLOW 107) chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Solvent Yellow 107 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Solvent Yellow 107 Use and application,Solvent Yellow 107 technical grade,usp/ep/jp grade.


Related News: Biogen research chief Alfred Sandrock said the FDA had painstakingly analyzed its clinical trial data over two years before reaching a conclusion. 2,2′-[(3,3′-dimethyl[1,1′-biphenyl]-4,4′-diyl)bis(azo)]bis[4-nonylphenol] manufacturer Production of J&J’s vaccine at the Baltimore site was halted by U.S. authorities in April and J&J was put in charge of manufacturing at the plant. 2,2′-[(3,3′-dimethyl[1,1′-biphenyl]-4,4′-diyl)bis(azo)]bis[4-nonylphenol] supplier Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS. 2,2′-[(3,3′-dimethyl[1,1′-biphenyl]-4,4′-diyl)bis(azo)]bis[4-nonylphenol] vendor Biogen research chief Alfred Sandrock said the FDA had painstakingly analyzed its clinical trial data over two years before reaching a conclusion. 2,2′-[(3,3′-dimethyl[1,1′-biphenyl]-4,4′-diyl)bis(azo)]bis[4-nonylphenol] factory An effective treatment for Alzheimer��s, which is estimated in 60%-70% of around 50 million dementia cases worldwide, could become one of the best-selling drugs globally.